Education and Work Experience
- 2006.09–2011.07: PhD in Pharmacology, Sun Yat-sen University
- 2011.08–2014.01: Postdoctoral Research, Biochemistry, NIH, USA
- 2014.02–2016.09: Postdoctoral Research, Vascular Biology, University of Rochester, USA
- 2016.10–2019.10: Research Assistant Professor, Vascular Biology, University of Rochester, USA
- 2020.01–Present: PI, Pharmacology, First Affiliated Hospital of USTC
-2024.01–Present: Humboldt fellow, Max Planck Institute for Heart and Lung Research, Germany
Academic Achievements and Impact
Focused on the pathogenesis of atherosclerosis and the development of natural cardiovascular drugs. Published in journals such as JCI, European Heart Journal, PNAS, STTT, and Pharmacological Reviews, with over 16K citations in BMJ, Nature Reviews Immunology, etc. Editorial board member for Cardiovascular Diabetology and others. Received the AHA Career Development Award (2018). Led projects funded by AHA, National Natural Science Foundation of China, NSFC-international (regional) collaborative research grant, and provincial key research gtants. Served as a review expert for the Hong Kong RGC since 2012 and external reviewer for NSFC-RGC collaborative research scheme
Current Projects (as Principal Investigator)
1. Project: LINC00084 and SART3 Upregulation of eNOS Expression for Vascular Homeostasis, National Natural Science Foundation; Funding: 550,000 RMB; Duration: 2021-01 to 2023-12
2. Project: Role and mechanism of DHH in preventing EndoMT and atherosclerosis; Funding: 490,000 RMB; Duration: 2024-01 to 2027-12
Main Research Areas (Recruitment Fields) and Content
Biology
Research on the pathogenesis of atherosclerosis and the development of natural cardiovascular drugs:
1. Molecular mechanisms of endothelial dysfunction
2. Molecular mechanisms of shear stress regulation in atherosclerosis
3. High-throughput and high-content screening of natural cardiovascular protective drugs
Representative Papers (Last Five Years)
1. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacological Reviews, 2021, 73:1-44
2. The novel coronary artery disease risk gene JCAD/KIAA1462 promotes endothelial dysfunction and atherosclerosis - European Heart Journal. 2019, 40(29):2398-2408
3. TRIM56 protects against non-alcoholic fatty liver disease via promoting the degradation of fatty acid synthase, Journal of Clinical Investigation, 2024,11: e166149 （cover story）
4. The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction, Signal Transduction and Targeted Therapy, 2021, 6: 266
5. A proteome-wide screen identifies the calcium binding proteins, S100A8/S100A9, as clinically relevant therapeutic targets in aortic dissection, Pharmacological Research, 2024, 199: 107029
Contact Information
Address: West Campus, School of Life Sciences, USTC, Annex Building
E-mail: sxu1984@ustc.edu.cn
Phone: 0551-63602683